pharmaphorum4d
Alexion finally has a buyer – and it's AstraZeneca with $39bn on the table
AG10 for ATTR cardiomyopathy and ALXN2040 or PNH patients with extravascular haemolysis (EVH). “Alexion has established itself as a leader in complement biology, bringing life-changing benefits ...
pharmaphorum6d
EU gives narrower label to Apellis, Sobi's PNH drug
which opted for a broad indication that included first-line treatment for PNH, and positioned pegcetacoplan as a direct competitor to AstraZeneca/Alexion's C5 inhibitors Soliris (eculizumab ...
Healio2d
FDA approves Soliris for patients aged 6 years and up with generalized myasthenia gravis
The FDA has approved an expanded indication of Soliris, an IV-administered monoclonal antibody for patients aged 6 years and ...
FDA Approves Expanded Use of Eculizumab (Soliris) for Pediatric Myasthenia Gravis, Bringing New Treatment Options for Children
The Muscular Dystrophy Association (MDA) welcomes the U.S. Food and Drug Administration (FDA) approval of the expanded indication of Alexion/AstraZeneca’s eculizumab (Soliris) for pediatric patients ...
Morningstar4d
FDA Approves Expanded Use of Eculizumab (Soliris) for Pediatric Myasthenia Gravis, Bringing New Treatment Options for Children
New York, March 10, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) welcomes the U.S. Food and Drug Administration (FDA) approval of the expanded indication of Alexion ...
Investing3d
Apellis Pharmaceuticals Inc (APLS)
Alexion Pharmaceuticals (NASDAQ:ALXN) is up 11% premarket on light volume in response to its announcement of successful results ...